Lymphogranuloma venereum (LGV) has emerged as an important cause of proctitis and proctocolitis in men who have sex with men; classical inguinal presentation is now increasingly uncommon. We report summary findings of an extensive literature review on LGV clinical presentation, diagnosis, and treatment that form the evidence base for the 2015 Centers for Disease Control and Prevention treatment guidelines for sexually transmitted diseases. Proctitis and proctocolitis are now the most commonly reported clinical manifestations of LGV, with symptoms resembling those of inflammatory bowel disease. Newer molecular tests to confirm LGV infection are sensitive and specific, but are generally restricted to research laboratory or public health settings. Doxycycline (100 mg twice daily for 21 days) remains the treatment of choice for LGV. Patients with rectal chlamydial infection and signs or symptoms of proctitis should be tested for LGV, or if confirmatory testing is not available, should be treated empirically with a recommended regimen to cover LGV infection.
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Lymphogranuloma venereum (LGV) is a condition caused by invasive serovars of Chlamydia trachomatis (L1, L2, or L3). Classically, LGV is characterized by the development of transient genital ulcer(s) or papule(s), followed by the appearance of tender inguinal and/or femoral lymphadenopathy (most commonly unilateral) with a characteristic "groove sign" formed by swollen, matted lymph nodes developing along the course of the inguinal ligament. Untreated, the infection may lead to long-term complications such as deep tissue abscess formation, strictures, fissures, and chronic pain [1, 2] .
In recent years, developed countries have experienced a shift in LGV epidemiological patterns and clinical presentation. Over the past decade, LGV has emerged in Europe and North America as a leading cause of proctitis and proctocolitis in men who have sex with men (MSM). Rectal ulcerations, bleeding, tenesmus, and lower abdominal cramping and pain are the primary clinical features, and prolonged infection can lead to the development of perirectal abscesses, fissures, and systemic symptoms such as fever, malaise, weight loss, and fatigue. Today in developed countries, LGV is predominantly associated with rectal infection, and the classical findings of inguinal lymphadenopathy are increasingly uncommon.
Diagnosis and treatment of LGV infections are paramount for preventing long-term consequences of infection, as well as preventing secondary spread to sex partners. Moreover, to the extent that LGV proctitis is increasingly identified in human immunodeficiency virus (HIV)-infected persons, there is concern for potential LGV enhancement of HIV acquisition or transmission. In this article, we report on our review of the literature on LGV and proctitis in support of updating and revising the evidence-based guidelines for treatment of sexually transmitted diseases (STDs) prepared by the US Centers for Disease Control and Prevention (CDC) [3] .
METHODS
In preparation for the expert guidelines panel convened by the CDC, we reviewed articles published from 1 January 2008 through 1 February 2013 and formulated key questions to address issues related to LGV management and treatment. Using the Medline database of the US National Library of Medicine, we searched for all articles containing "lymphogranuloma venereum" or "LGV" (all documents) in the title, abstract, substance word, subject heading word, keyword, protocol supplementary concept, rare disease supplementary concept, or unique identifier. In addition, abstracts relevant to LGV treatment from professional conference proceedings were reviewed, including the International Society for Sexually Transmitted Diseases Research, National Sexually Transmitted Disease Prevention Conference, Infectious Disease Week, Interscience Conference on Antimicrobial Agents and Chemotherapy, and Conference on Retroviruses and Opportunistic Infections. Additionally, international treatment guidelines, workshop papers, and gray literature addressing LGV treatment were examined. Articles and abstracts were systematically reviewed for content related to new developments in LGV clinical presentation, diagnosis, and treatment since the previous STD treatment guidelines update process in 2009. A total of 45 references were included in our final review, and key findings were summarized in the tables of evidence for the expert panel (Table 1) .
LGV CLINICAL MANIFESTATIONS Most case series and case reports describe clinical manifestations of LGV among MSM, and most of these individuals have been HIV infected . Proctitis and proctocolitis are the most commonly reported clinical manifestations of LGV in several case series [4-6, 16, 21] , with findings that resemble, and may be confused with, inflammatory bowel disease. Symptoms include rectal bleeding, pain, tenesmus, mucoid discharge, constipation, or hematochezia [10] . Gram stain of the anorectal discharge smear commonly shows elevated white blood cell counts (>10 per high-power field) [5, 28, 32] . Colonoscopic examination commonly reveals rectal ulcers with erythema and friability, with mucosal biopsies demonstrating lymphohistiocytic infiltrates, crypt abscesses, or granulomatous changes [4, 6, 8, 10, 13, 21] . Genital tract infection with lymphadenopathy and bubo formation is relatively uncommon [5, 7, 24] . Reactive polyarthropathy, with or without conjunctivitis, has been noted in several case reports; the most commonly affected joints included the wrist, knee, ankle, or elbow [9, 18, 26, 29] . Zoonotic transmission has also been described [33] . Although most rectal LGV among MSM appears to be symptomatic, some investigators have noted that asymptomatic infections can occur [5, 30, 31] .
LGV DIAGNOSIS Historically, LGV diagnosis has been based on clinical presentation coupled with appropriate serologic findings (microimmunofluorescence titers >1:256 or complement fixation titers >1:64) [3] . However, criteria for serologic test interpretation have not been standardized, nor has test performance been validated for rectal infections. Numerous research teams have developed novel molecular methods to confirm LGV infection from clinical material ( particularly anorectal swabs in MSM) [34] [35] [36] [37] [38] [39] . These methods focus on confirming LGV-associated serovars through sequencing of the outer membrane protein A (ompA) gene, or through the use of real-time polymerase chain reaction to identify an L2b-specific deletion in the polymorphic membrane protein H (pmpH) gene, or by combining C. trachomatis detection and genotyping with reverse hybridization assay. Unfortunately, amplified sequencing tests are not commercially available or cleared by the US Food and Drug Administration for use in the United States, and access is restricted to research centers and public health laboratories that have developed such assays. Additional LGV-specific serologic tests are also in development (eg, immunoglobulin A anti-MOMP) [40] . The lack of standardized and validated laboratory assays for use in clinical settings means that, in most circumstances, the diagnosis of LGV is typically based on epidemiological and clinical findings, confirmation of C. trachomatis infection by routinely available nucleic acid amplification tests (which are positive in both LGV and non-LGV chlamydial infections), and the exclusion of other potential etiologies of proctocolitis, lymphadenopathy, or genital ulcers. In clinic-based cohorts in Australia, the Netherlands, and the United Kingdom, significant numbers of patients (7%-23%) with rectal chlamydial infection and either signs or symptoms of proctitis were found to have an LGV strain of chlamydia [5, 20, 41] . The prevalence of LGV among patients with symptomatic rectal chlamydial infection in the United States is unknown, given the absence of systematic surveillance or commercially available assays.
LGV TREATMENT More than half a century of clinical experience supports the use of doxycycline, 100 mg twice daily for 21 days, as the treatment of choice for LGV [2, 3, 42] . This recommendation is based on reported treatment efficacy in numerous case series, coupled with a favorable pharmacokinetic profile, minimal toxicity, and convenient dosing. A 3-week duration of therapy is required because LGV infections are more invasive and more difficult to eradicate than uncomplicated genital tract infections, which typically respond to 1 week of treatment. Erythromycin base, 500 mg 4 times daily for 21 days, is a reliable alternative treatment with many years of demonstrated use efficacy, although gastrointestinal intolerance and inconvenient dosing may limit its utility. In addition to antimicrobial therapy, local management of buboes (by aspiration through intact skin, or incision and drainage) may also be considered to prevent the development of ulcerations or fistulous tracts. (10) , MSM (9), bleeding (9), ulcerations (7), pain (6), tenesmus (4).
de Vrieze et al [5] Cross-sectional prevalence study
LGV infection (confirmed by PCR of pmpH)
Clinical correlates of
LGV and non-LGV chlamydial infection 27.2% of pts with rectal LGV had no signs or symptoms; 85.3% of symptomatic pts had anorectal Gram stain smear with >10 PMNLs/high-power field
Inguinal LGV cases were rare, and were less likely to be HIV coinfected.
Gallegos et al [6] Case series 3 pts with rectal LGV (US)
LGV First case report of female with bubonic LGV caused by L2b serovariant (probably from bisexual male partners).
Cunningham et al [8] Case report 1 pt with rectal LGV (US)
LGV Kennedy & Higgins [9] Case report 1 pt with LGV (UK)
LGV proctitis with reactive arthropathy
LGV infection
LGV proctitis was followed by reactive arthropathy that mimicked DVT (acute swelling of lower limb)
LGV may have prevented reactive arthropathy.
Geisler et al [10] Case report 1 pt with LGV (US)
LGV proctocolitis (L2b variant confirmed by ompA sequencing) Case series 4 pts with LGV (Czech Republic)
LGV proctitis (LGV genotype confirmed by PCR amplification of pmpH)
Clinical correlates of LGV infection
Symptoms included intense rectal pain, blood in stool, mucus discharge, tenesmus, constipation. Endoscopy showed congested, irritated mucus membranes.
All were HIV + MSM. Lymph node abscess occurred in 1 pt. Treatment with oral doxycycline was curative.
VargasLeguas et al [12] Case LGV proctitis Clinical correlates of LGV infection
Gastrointestinal symptoms raised suspicion of IBD.
All cases were MSM. Threequarters were HIV + . All responded to doxycycline. Heras et al [17] Case series 15 pts with LGV (Spain)
LGV proctocolitis (L2 serovar confirmed with reverse hybridization) Singhrao et al [19] Case report 2 pts with LGV (UK)
LGV rectal infection (confirmed LGVassociated serovar on rectal swab)
Both pts presented with isolated perianal ulcers.
Both pts responded to 3 wk of doxycycline. High index of suspicion required for nonproctitis presentations. Bissessor [20] Case series 25 pts with LGV (Australia)
LGV infection (confirmed by omp1 genotyping)
LGV found in 7.2% of pts with chlamydial infection and symptomatic proctitis 72% of cases coinfected with HIV.
Soni et al [21] Case series 15 pts with LGV (UK)
LGV proctitis (confirmed with LGV-specific DNA)
Clinical and endoscopic correlates of LGV infection
Retrospective analysis. Pts had mucosal ulcers, cryptitis, crypt abscesses, and granulomas.
LGV proctitis closely resembles IBD.
Castro et al [22] Case series 9 pts with chronic proctitis (Portugal)
LGV proctitis (confirmed by rt-PCR/omp1 gene amplification)
Clinical correlates of LGV infection
Two patients confirmed infected with L2b serovar, with ≥10 000 antibody titers.
First 2 cases of LGV in Portugal.
Kamarashev et al [23] Case series 12 pts with proctitis (Switzerland)
LGV proctitis (confirmed serovar L2 by PCR) LGV infection Clinical correlates of LGV infection
Cases were predominantly MSM, most were HIV + . Anorectal symptoms were most common.
Little evidence of spread to the wider population.
Vall-Mayans & Caballero [26] Case series 7 pts with proctitis (Spain)
LGV infection (confirmed serovar L)
Clinical correlates of LGV infection
Mean duration of proctitis symptoms 28 d
All cases were MSM, HIV + .
Vall-Mayans et al [27] Case report 1 pt with proctitis and arthropathy (Spain)
LGV infection (confirmed by rt-PCR)
Proctitis, conjunctivitis, and arthritis affecting knees and right elbow.
LGV and SARA -responded to doxycycline ×21 d. Heras et al [28] Case report 1 pt with proctitis (Spain)
LGV [29] Case report 1 pt with proctitis and reactive arthritis (France)
LGV infection (confirmed L2b serovar by PCR of omp1)
Pt had fever, weight loss, purulent rectal discharge, tenesmus, followed by conjunctivitis and oligoarthritis (wrist, knee, ankles). LGV infection (confirmed by PCR or clinical/ epidemiologic criteria)
Symptoms included anal discharge, rectal erosion, nodular erosive lesions, and inguinal abscess.
All pts MSM, most HIV + .
Khorvash et al [33] Case report 1 pt with inguinal and femoral mass (Iran)
LGV infection (confirmed by histopathology and IgG titer)
History of sexual contact with mare 14 d before illness onset Zoonotic transmission.
LGV laboratory diagnosis Almeida et al [34] Laboratory analysis 51 Chlamydia strains (LGV, ocular, urogenital)
Analyses of polymorphisms and phylogeny of 48 Inc proteins Amino acid differences between LGV and ocular/urogenital isolates
LGV strains showed significant AA differences; 10 Inc genes likely under positive selective pressure. Subtle nonsilent mutations contribute to tropism/ invasiveness of LGV strains.
Inhibition of phagolysosomal fusion is hypothesized to account for LGV invasiveness. Cross-sectional study 140 CT NAATpositive rectal and pharyngeal swabs
Genotyping by pmpH and ompA rt-PCR Detection of LGV and non-LGV CT types 114/140 (81%) were successfully typed by pmpH PCR (104 non-LGV, 9 LGV, 1 both). Of the Ltypes, 6 were L2b, and 2 were L2 by ompA PCR and sequencing. L types were mostly rectal.
Genotyping by pmpH PCR is feasible in diagnostic labs that already perform NAATs to detect chlamydia.
Mobius et al [36] Laboratory assay development
CT L serovar primers Development of rt-PCR protocol
Detection of LGVassociated L serovars
Step-by-step description of a protocol for using TaqMan multiplex rt-PCR to detect LGVassociated serovars
Allows subtyping of L1, L2, and L3 variants.
Verweij et al [37] Laboratory assay development CT L2b serovars Development of rapid L2b-specific PCR Detection of L2b-specific serovar
Description of an L2b-specific primer/probe set for rapid identification of L2b variant using rt-PCR Based on unique insertion in pmpH gene; avoids laborious ompA sequencing.
Quint et al [38] Laboratory assay development 50 CT-positive specimens (Aptima Combo 2)
Detection of CT by omp1 sequencing, CT-DT assay, and pmpH rt-PCR
Differentiation of LGV and non-LGV infections
CT-DT assay was best for distinguishing LGV from non-LGV infections.
pmpH rt-PCR assay performed well for LGV, but missed substantial numbers of non-LGV infections. Azithromycin may also be effective for treating LGV, given its efficacy against other genital tract and systemic non-LGV chlamydial infections. However, clinical evidence is lacking to support the routine use of azithromycin, and multiple doses may be required to provide a similar level of sustained antimicrobial activity (eg, 1.0 g weekly for 3 weeks) [41] . Fluoroquinolone antibiotics with demonstrated antichlamydial activity (such as ofloxacin or levofloxacin) may also be effective for treating LGV, but no comparative treatment trials have been published, and extended treatment durations are likely required. Moxifloxacin (400 mg daily for 10 days) has been reported as effective treatment for doxycycline treatment failure [43] .
Many patients with LGV are HIV infected, particularly MSM with proctocolitis. These patients respond well to recommended treatment regimens, although some patients may have a delayed resolution of symptoms and may benefit from prolonged courses of treatment. In the absence of a diagnostic assay for LGV, MSM with acute proctitis and a positive rectal chlamydia test should be offered presumptive treatment with a recommended regimen for LGV.
Treatment of asymptomatic rectal chlamydial infections is controversial. Some investigators have raised concerns about the efficacy of single-dose azithromycin in this context. Retrospective analyses of asymptomatic rectal chlamydia treated with 1 g of azithromycin found that >10% of patients who returned for test of cure were persistently positive [45, 46] . Moreover, prospective observational studies have documented persistent positivity rates of 16%-20% among persons who were treated with azithromycin, compared with only 1%-10% among persons who were treated with doxycycline [44, 47, 48] . Clearly, additional research is required to clarify the optimal treatment regimen for patients with asymptomatic rectal chlamydial infection.
CONCLUSIONS
LGV continues to be an important cause of morbidity among MSM, and clinicians should have a high index of suspicion for LGV when assessing patients with proctitis or symptoms suggestive of inflammatory bowel disease. Diagnosing LGV remains a challenge, although newer molecular tests show great promise and are likely to become more widely available in the coming years. Serologic assays are limited by lack of sensitivity and specificity, but can be helpful in providing a presumptive diagnosis of LGV in the proper clinical context.
Our review of the literature supports the current treatment recommendation of doxycycline 100 mg twice daily for 21 days. Alternative agents such as azithromycin are promising due to their antichlamydial activity, but extended treatment regimens are likely required. HIV-infected persons should be treated with standard LGV regimens, but extended treatment courses may be required if symptom resolution is delayed.
